➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Express Scripts
Dow
AstraZeneca
Boehringer Ingelheim

Last Updated: September 24, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for MEK162


Email this page to a colleague

« Back to Dashboard

What is the drug development status for MEK162?

MEK162 is an investigational drug.

There have been 62 clinical trials for MEK162. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2013.

The most common disease conditions in clinical trials are Melanoma, Neoplasms, and Carcinoma. The leading clinical trial sponsors are Array BioPharma, National Cancer Institute (NCI), and Pfizer.

There are five hundred and eight US patents protecting this investigational drug and four international patents.

Recent Clinical Trials for MEK162
TitleSponsorPhase
Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System MetastasesM.D. Anderson Cancer CenterPhase 2
Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic CancerRoswell Park Cancer InstituteEarly Phase 1
PF-07284892 in Participants With Advanced Solid TumorsPfizerPhase 1

See all MEK162 clinical trials

Clinical Trial Summary for MEK162

Top disease conditions for MEK162
Top clinical trial sponsors for MEK162

See all MEK162 clinical trials

US Patents for MEK162

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
MEK162 ⤷  Free Forever Trial Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity The University of North Carolina at Chapel Hill (Chapel Hill, NC) ⤷  Free Forever Trial
MEK162 ⤷  Free Forever Trial Compounds and compositions as protein kinase inhibitors Array BioPharma Inc. (Boulder, CO) ⤷  Free Forever Trial
MEK162 ⤷  Free Forever Trial Anti-CS1 antibodies and antibody drug conjugates AbbVie Biotherapeutics Inc. (Redwood City, CA) ⤷  Free Forever Trial
MEK162 ⤷  Free Forever Trial .beta.-substituted .beta.-amino acids and analogs as chemotherapeutic agents and uses thereof Quadriga Biosciences, Inc. (Los Altos, CA) ⤷  Free Forever Trial
MEK162 ⤷  Free Forever Trial Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (Knoxville, TN) ⤷  Free Forever Trial
MEK162 ⤷  Free Forever Trial Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO) ⤷  Free Forever Trial
MEK162 ⤷  Free Forever Trial 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof Samumed, LLC (San Diego, CA) ⤷  Free Forever Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for MEK162

Drugname Country Document Number Estimated Expiration Related US Patent
MEK162 Australia AU2015244171 2034-04-11 ⤷  Free Forever Trial
MEK162 Australia AU2015244179 2034-04-11 ⤷  Free Forever Trial
MEK162 Canada CA2945128 2034-04-11 ⤷  Free Forever Trial
MEK162 Canada CA2945129 2034-04-11 ⤷  Free Forever Trial
MEK162 China CN106414451 2034-04-11 ⤷  Free Forever Trial
MEK162 China CN106459063 2034-04-11 ⤷  Free Forever Trial
MEK162 European Patent Office EP3129377 2034-04-11 ⤷  Free Forever Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Merck
Colorcon
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.